SCL Lifesciences Limited is a pharmaceutical company founded in 1993 and headquartered in India, focused on the development and manufacture of active pharmaceutical ingredients (APIs), advanced intermediates, and contract development and manufacturing services.

The company operates across both domestic and international markets, with a strong export footprint and customers in regulated regions such as Europe, the United States, and Japan. Its manufacturing operations are supported by facilities that comply with global regulatory standards, including EU-GMP, US FDA, and other international requirements.

SCL Lifesciences positions itself as a CDMO partner offering integrated services from early-stage development through to commercial manufacturing. Its capabilities span process development, scale-up, and large-scale production, supported by research infrastructure and expertise in complex chemistries and high-potency compounds.

The company also supports innovation in emerging areas such as mRNA vaccine components, alongside its core API and intermediates business, enabling pharmaceutical partners to advance both small molecule and specialised therapeutic programmes.

Key products and services

Active Pharmaceutical Ingredients (APIs)
Development and manufacture of high-quality APIs, including niche and high-potency molecules.

Advanced Intermediates
Supply of key intermediates used in pharmaceutical synthesis and drug development.

CDMO / Contract Manufacturing Services
End-to-end development and manufacturing support from concept to commercialisation, including scale-up and regulatory compliance.

Analytical Services
Analytical method development and testing using advanced instrumentation and compliant systems.

mRNA Vaccine Ingredients
Supply of components used in vaccine manufacturing to support emerging biologics and advanced therapies.

SCL Lifesciences combines manufacturing scale, regulatory compliance, and CDMO expertise to support pharmaceutical companies across development and commercialisation stages. With a focus on APIs, intermediates, and emerging technologies, the company continues to expand its role as a contract manufacturing partner for global pharmaceutical and biotechnology clients.